Side-by-side · Research reference

CardiogenvsMGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-StrongHUMAN-REVIEWED14/55 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

MGF

IGF-1Ec Splice Variant · Muscle-Specific

IGF-1EcSplice variantArmakolas 2016

24-AASynthetic E-domain

Animal onlyHuman evidence

SQ · Research context only

01Mechanism of Action

Parameter

Cardiogen

MGF

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Satellite cells (Pax7+) in skeletal muscleMoore 2018

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Satellite cell proliferation, myoblast differentiation, muscle fiber repair

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016 Vassilakos 2017

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

MGF

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

—

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

—

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Animal models + in vitro only

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

—

Synthetic peptide

—

24-amino-acid E-domain sequence

Corresponds to human IGF-1Ec exons 4-6 region.

Rodent cardiac model

—

200 μg/kg via peptide-eluting microstructures

Post-MI injection; improved ejection fraction by 8 weeks.

Acute delivery (mouse MI)

—

Single bolus within 12 hrs post-infarctionShioura 2014

Delayed decompensation; no human protocol established.

Human evidence

—

None — no published clinical trials

All dosing extrapolated from animal models.

Detection in doping

—

Full-length MGF detected via LC-MS in illicit productsThevis 2014

WADA-prohibited since 2005; no therapeutic indication.

04Side Effects & Safety

Parameter

Cardiogen

MGF

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Human safety data

—

None — no clinical trials published

Theoretical IGF-1 axis risk

—

Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)

Tumor promotion

—

IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer

Antibody development

—

Unknown — no longitudinal human exposure data

Local injection reaction

—

Presumed similar to other peptides (erythema, induration) — no direct evidence

Dysregulated expression with age

—

Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

MGF

·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
·No established therapeutic use — investigational only

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

MGF

·Family history of IGF-1-axis malignancies
·Use outside research setting

05Administration Protocol

Parameter

Cardiogen

MGF

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.

3. Timing

Variable — often evening injection. No established circadian preference.

Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015 Shioura 2014

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

MGF

+ BPC-157

Multi-pathway

View BPC-157 →

MGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.

MGF: No established dose
BPC-157: 250–500 mcg SQ near injury site
Context: Animal models only
Primary benefit: Theoretical multi-tissue repair (muscle + tendon/ligament)

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.

MGF: No established dose
TB-500: 2–5 mg SQ weekly
Context: Animal models only
Primary benefit: Satellite cell activation + enhanced migration/angiogenesis